Temisis Therapeutics competitors and similar companiesClear all

Temisis Therapeutics's competitors and similar companies include Sosei Heptares, Camurus and Heron Therapeutics.

	Temisis Therapeutics Temisis Therapeutics is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing an inflammatory component.	Sosei Heptares Sosei Heptares is a biopharmaceutical company that specializes in drug development.	Camurus Camurus is a research-based pharmaceutical company that develops medicines for severe and chronic conditions.	Heron Therapeutics Heron Therapeutics is a biotechnology company engaged in drug discovery and development.
Founding Date	Founding Date N/A	Founding Date 1990	Founding Date 1991	Founding Date 1983
Type	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy
Locations	Locations Vandœuvre-lès-Nancy, FR HQ	Locations Tokyo, JP HQ Dublin, IE Cambridge, GB London, GB	Locations Lund, SE HQ Sydney, AU Mannheim, DE Duxford, GB	Locations San Diego, US HQ
Employees	Employees 2	Employees 199	Employees 157	Employees 30235% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 1.8 b	Valuation ($) 1.4 b	Valuation ($) 132.9 m
Employee Rating	Employee Rating N/A	Employee Rating 3.9	Employee Rating 5	Employee Rating 3.6
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ¥15.6b (FY, 2022)	Revenue (est.) kr956.3m (FY, 2022)	Revenue (est.) $107.7m (FY, 2022)
Cost of goods	Cost of goods N/A	Cost of goods ¥490m (FY, 2022)	Cost of goods kr90.2m (FY, 2022)	Cost of goods $54.9m (FY, 2022)
Gross profit	Gross profit N/A	Gross profit ¥15.7b (FY, 2022)	Gross profit kr866.9m (FY, 2022)	Gross profit $52.8m (FY, 2022)
Net income	Net income N/A	Net income ¥1.8b (FY, 2022)	Net income kr55.6m (FY, 2022)	Net income ($182m) (FY, 2022)